Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: Developments and future prospects

Biomarkers in Medicine

Volumn 2, Issue 2, 2008, Pages 165-180

  Shariat, Shahrokh F ^a   Karam, Jose A ^a   Raman, Jay D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Bladder tumor antigen; Fluorescence in situ; Hematuria; Hybridization; Nuclear matrix protein 22

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; DNA; FAS ANTIGEN; FIBRIN; FIBRINOGEN; HYALURONIC ACID; HYALURONIDASE; MICROSATELLITE DNA; NUCLEAR MATRIX PROTEIN 22; PROTEIN BLCA 1; PROTEIN BLCA 4; SIALYL LEWIS X ANTIGEN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TUMOR ANTIGEN; TUMOR MARKER;

BLADDER CANCER; BLADDER CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CLINICAL STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRIN METABOLISM; FIBRINOGEN METABOLISM; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEMATURIA; HUMAN; INTERMETHOD COMPARISON; NON INVASIVE MEASUREMENT; PATIENT MONITORING; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; UNITED STATES; URINALYSIS; URINE CYTOLOGY; UROTHELIUM;

EID: 44449084353     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.2.165     Document Type: Review

References (156)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130 (2006).
2. Prout GR Jr, Barton BA, Griffin PP, Friedell GH: Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J. Urol. 148, 1413-1419 (1992).
3. Pagano F, Bassi P, Galetti TP et al.: Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with ap emphasis on the inadequacy of the tumor, nodes and metastases classification. J. Urol. 145, 45-50 (1991).
4. Heney NM, Ahmed S, Flanagan MJ et al.: Superficial bladder cancer: progression and recurrence. J Urol. 130, 1083-1086 (1983).
5. Heney NM: Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol. Clin. North Am. 19, 429-433, (1992).
6. Murphy WM: Diseases of urinary bladder, urethra, ureters and renal pelvis. In: Urological Pathology. Murphy WM (Ed.). WB Saunders, PA, USA (1989).
7. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP: Biology and management of bladder cancer. N. Engl. J. Med. 322, 1129-1138 (1990).
8. Skinner DG, Lieskovsky G: Management of invasive and high-grade bladder cancer. In: Diagnosis and Managment of Genitourinary Cancer (2nd Edition). Skinner DGE, Lieskovsky GE (Eds). WB Saunders, PA, USA (1988).
9. Stein JP, Grossfeld GD, Ginsberg DA et al.: Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol. 160, 645-659 (1998).
10. van der Poel HG, Debruyne FM: Can biological markers replace cystoscopy? An update. Curr. Opin. Urol. 11, 503-509 (2001).
11. Soloway MS, Murphy W, Rao MK, Cox C: Serial multiple-site biopsies in patients with bladder cancer. J. Urol. 120, 57-59 (1978).
12. Brausi M, Collette L, Kurth K et al.: Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional eell carcinoma ofthe bladder: a combined analysis of seven EORTC studies. Eur. Urol. 41, 523-531 (2002).
13. Herr HW: The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol. 162, 74-76 (1999).
14. Svatek RS, Lee D Lotan Y: Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard? Urology 66, 65-68 (2005).
15. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M: Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J. Urol. 171, 135-138 (2004).
16. Jichlinski P, Guillou L, Karlsen SJ et al.: Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J. Urol. 170, 226-229 (2003).
17. Wiener FIG, Vooijs GP, van't Hof-Grootenboer B: Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol. 37, 163-169 (1993).
18. Karakiewicz PI, Benayoun S, Zippe C et al.: Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 97, 997-1001 (2006).
19. Lokeshwar V, Soloway M: Current bladder tumor tests: does their projected utility fulfill clinical necessity? J. Urol. 165. 1067-1077 (2001).
20. Svatek RS, Sagalowsky AI, Lotan Y: Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol. Oncol. 24, 338-343 (2006).
21. Lotan Y, Svatek RS, Sagalowsky AI: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 107(5), 982-990 (2006).
22. Lotan Y, Roehrborn CG: Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol. 167, 75-79 (2002).
23. Gregoire M, Fradet Y, Meyer F et al.: Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. J. Urol. 157, 1660-1664 (1997).
24. Leyh H, Marberger M, Conort P et al.: Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur. Urol. 35, 52-56 (1999).
25. Konety BR, Metro MJ, Melham MF, Salup RR: Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract. Urol. Int. 62, 26-30 (1999).
26. Landman J, Chang Y, Kavaler E. Droller MJ, Liu BC: Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 52, 398-402 (1998).
27. Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A: NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res. 19, 2621-2623 (1999).
28. Takashi M, Schenck U, Kissel K, Leyh H, Treiber U: Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients. Int. Urol. Nephrol. 31, 189-196 (1999).
29. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I: Noninvasive detection of bladder cancer with the BTA stat test. J. Urol. 161, 443-446 (1999).
30. Lotan Y, Roehrborn CG: Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and metaanalyses. Urology 61, 109-118 (2003).
31. Grossfeld GD, Litwin MS, Wolf JS Jr et al.: Evaluation of asymptomatic microscopic hematuria in adults: the american urological association best practice policy-part 1, definition (detection, prevalence, and etiology). Urology 57, 599-603 (2001).
32. Britton JP Dowell AC, Whelan P, Harris CM: A community study of bladder cancer screening by the detection of occult urinary bleeding. J. Urol. 148, 788-790 (1992).
33. Messing EM, Young TB, Hunt VB et al.: Home screening for hematuria: results of a multiclinic study. J. Urol. 148, 289-292 (1992).
34. Messing EM, Young TB, Hunt VB et al.: Hematuria home screening: repeat testing results. J. Urol. 154, 57-61 (1995).
35. Murakami S, Igarashi T, Hara S, Shimazaki J: Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. J. Urol. 144, 99-101 (1990).
36. Messing EM, Young TB, Hunt VB, Emoto SE, Wehbie JM: The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J. Urol. 137, 919-922 (1987).
37. Mariani AJ, Luangphinith S, Loo S, Scottolini A, Hodges CV: Dipstick chemical urinalysis: an accurate cost-effective screening test. J. Urol. 132, 64-66 (1984).
38. Woolhandler S, Pels RJ, Bor DH, Himmelstein DU, Lawrence RS: Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematurb and proteinuria. JAMA 262, 1214-1219 (1989).
39. Sutton JM: Evaluation of hematuria in adults. JAMA 263, 2475-2480 (1990).
40. Ramakumar S, Bhuiyan J, Besse JA et al.: Comparison of screening methods in the detection of bladder cancer. J. Urol. 161, 388-394 (1999).
41. Messing EM, Golijanin D, Stephenson L et al.: Long-term outcome of hematuria home screening for bladder cancer (BC). In: American Urological Association Annual Meeting. Atlanta, GA, USA, 20-25 May (2006).
42. Johnston B, Morales A, Emerson L, Lundie M: Rapid detection of bladder cancer: a comparative study of point of care tests. J. Urol. 158, 2098-2101 (1997).
43. Kinders R, Jones T, Root R et al.: Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin. Cancer Res. 4, 2511-2520 (1998).
44. Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M: Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J. Urol. 159, 1876-1880 (1998).
45. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A: Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J. Urol. 162, 53-57 (1999).
46. Gutierrez Banos JL, Martin Garcia B, Hernandez Rodriguez R et al.: Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy. Arch. Esp. Urol. 51, 178-782 (1998).
47. Leyh H, Mazeman E: Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur. Urol. 32, 425-428 (1997).
48. Nasuti JF, Gomella LG, Ismial M, Bibbo M. Utility of the BTA stat test kit for bladder cancer screening. Diagn. Cytopathol. 21, 27-29 (1999).
49. Oge O, Kozaci D, Gemalmaz H: The BTA stat test is nonspecific for hematuria: an experimental hematuria model. J. Urol. 167, 1318-1319 (2002).
50. Malkowicz SB: The applicationl of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol. Clin. North Am. 27, 63-73 (2000).
51. Thomas L, Leyh H, Marberger M et al.: Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin. Chem. 45, 472-477 (1999).
52. Mahnert B, Tauber S, Kriegmair M et al.: BTA-TRAK - a useful diagnostic tool in urinary bladder cancer? Anticancer Res. 19, 2615-2619 (1999).
53. Irani J, Desgrandchamps F, Millet C et al.: BTA stat and BTA TRAK: a comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder. Eur. Urol. 35, 89-92 (1999).
54. Heicappell R, Wettig IC, Schostak M et al.: Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Eur. Urol. 35, 81-87 (1999).
55. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL: Clinical evluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors.
56. Abbate I, D'Introno A, Cardo et al.: Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer. Anticancer Res. 18, 3803-3805 (1998).
57. Fradet Y, Lockhard C: Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can. J. Urol. 4, 400-405 (1997).
58. Olsson H, Zackrisson B: ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcimoma. Scand. J. Urol. Nephrol. 35, 280-282 (2001).
59. Mian C. Pycha A, Wiener H, Haitel A, Lodde M, Marberger M: Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J. Urol. 161, 1486-1489 (1999).
60. Vriesema JLJ, Atsma F, Kiemeney LA, Peelen WP. Wities JA, Schalken JA: Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 58, 367-371 (2001).
61. Gordon JN, Shu WP, Schlussel RN, Droller MJ, Liu BCS: Altered extracellular matrices influence cellular processes and nuclear matrix organisations of overlying human bladder urothelial cells. Cancer Res. 53, 4971-4977 (1993).
62. Berezney R, Coffey DS: Identification of a nuclear protein matrix. Biochem. Biophys. Res. Commun. 60, 1410-1417 (1974).
63. Pardoll DM, Vogelstein B, Coffey DS: A fixed site of DNA replication in eukaryotic cells. Cell 19, 527-536 (1980).
64. Compton DA, Cleveland DW: NuMA is required for the proper completion of mitosis. J Cell Biol. 120, 947-957 (1993).
65. Shelfo SW, Soloway MS: The role of nuclear matrix protein 22 in the detection of persistent or recurrent transltional-cell cancer of the bladder. Wold J. Urol. 15, 107-111 (1997).
66. Miyanaga N, Akaza H, Tsukamoto T et al.: Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int. J. Urol. 6, 173-177 (1999).
67. Hughes JH, Katz RL, Rodriguez-Villanueva J et al.: Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn. Cytopathol. 20, 285-290 (1999).
68. Del Nero A, Esposito N, Curro A et al.: Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test. Eur. Urol. 35, 93-97 (1999).
69. Serretta V, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I: Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 52, 793-796 (1998).
70. Witjes JA, van der Poel HG, van Balken MR, Debruyne FM, Schalken JA: Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur. Urol. 33, 387-391 (1998).
71. Stampfer D, Carpinito G, Rodriguez-Villanueva J et al.: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J. Urol. 159, 394-398 (1998).
72. Soloway MS, Briggman JV, Carpinito GA et al.: Use of a new tumor marker, urinary NMP2 2 iin the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol. 156, 363-367 (1996).
73. Ponsky LE, Sharma S, Pandrangi L et al.: Screening and monitoring for bladder cancer. refining the use of NMP22. J. Urol. 166, 75-78 (2001).
74. Shariat SF, Casella R, Wians FH Jr et al.: Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur. Urol. 45, 304-313 (2004).
75. Shariat SF, Zippe C, Ludecke G et al.: Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J. Urol. 173, 1518-1525 (2005).
76. Shariat SF, Lotan Y, Sanchez-Carbayo M et al.: Variability in the performance of nuclear matrix protein 22 in the detection of bladder cancer. In: American Urologic Association Annual Meeting. Atlanta, GA, USA, 20-25 May 2006.
77. Grossman HB, Soloway M, Messing et al.: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295, 299-305 (2006).
78. Junker K, Boerner D, Schulze W, Utting M, Schubert J, Werner W: Analysis of genetic alterations in normal bladder urothelium. Urology 62, 1134-1138 (2003).
79. Hailing KC: Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev. Mol. Diagn. 3, 507-519 (2003).
80. Pycha A, Mian C, Haitel A, Hofbauer J. Wiener H, Marberger M: Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J. Urol. 157, 2116-2119 (1997).
81. Skacel M, Fahmy M, Brainard JA et al.: Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J. Urol. 169, 2101-2105 (2003).
82. Friedrich MG, Toma MI, Hellstern A et al.: Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int. 92, 911-914 (2003)
83. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P: Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am. J. Clin. Pathol. 116, 79-86 (2001).
84. Hailing KC, King W, Sokolova IA et al.: A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J. Urol 167, 2001-2006 (2002).
85. Kipp BR, Karnes RJ, Brankley SM et al.: Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 173, 401-404 (2005).
86. Mengual L, Marin-Aguilera M, Ribal MJ et al.: Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. Eur. Urol. 52, 752-759 (2007).
87. Heicappell R, Schostak M, Müller M, Miller K: Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder. Scand. J. Clin. Lab. Invest. 60, 275-282 (2000).
88. Mian C, Lodde M, Hattel A, Vigl EE, Marberger M, Pycha A: Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology 55, 223-226 (2000).
89. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Woodman AC: The early detection and diagnosis of bladder cancer: a critical review of the options. Eur. Urol. 39, 619-633 (2001).
90. Mian C, Lodde M, Haitel A, Egarter Vigi E, Marberger M, Pycha A: Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 56, 228-231 (2000).
91. Konety BR, Getzenberg R: Urine based markers of urological malignancy. J. Urol. 165, 600-611 (2001).
92. Halachmi S, Linn JF, Amiel GE, Moskovitz B, Nativ O: Urine cytology, tumour markers and bladder cancer. Br. J. Urol. 82, 647-654 (1998).
93. Pirtskalaishvili G, Getzenberg RH, Konety BR: Use of urine-based markers for detection and monitoring of bladder cancer. Tech, Urol. 5, 179-184 (1999).
94. Schmetter BS, Habicht KK, Lamm DL et al.: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J. Urol. 158, 801-805 (1997).
95. Wajsman Z, Williams PD, Greco J, Murphy GP: Further study of fibrinogen degradation products in bladder cancer detection. Urology 12, 659-661 (1978).
96. Konety BR, Nguyen TS, Dhir R et al.: Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin. Cancer Res. 6, 2618-2625 (2000).
97. Konety BR, Nguyen TS, Brenes G et al.: Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J. Urol. 164, 634-639 (2000).
98. Van Le TS, Myers J, Konety BR, Barder T, Getzenberg RH: Functional characterization of the bladder cancer marker, BLCA-4. Clin. Cancer Res. 10, 1384-1391 (2004).
99. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH: Highly specific urine-based marker of bladder cancer. Urology 66, 1256-1260 (2005).
100. Knudson W: Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am. J. Pathol. 148, 1721-1726 (1996).
101. Lokeshwar VB, Obek C, Soloway MS, Block NL: Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res. 57, 773-777 (1997).
102. Lokeshwar VB, Block NL: HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol. Clin. Narth Am. 27, 53-61 (2000).
103. Pham HT, Block NL, Lokeshwar VB: Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res. 57, 778-783 (1997).
104. Decenzo JM, Howard P, Irish CE: Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma. J. Urol. 114, 874-878 (1975).
105. Golijanin D, Sherman Y, Shapiro A, Pode D: Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 46, 173-177 (1995).
106. Pode D, Gonjanin D, Sherman Y, Lebensart P, Shapiro A: Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J. Urol. 159, 389-392 (1998).
107. van Rhijn BW, Lurkin I, Kirkels WJ, van der Kwast TH, Zwarthoff EC: Microsatellite analysis - DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a Phase II trial. Cancer 92, 768-775 (2001).
108. Czerniak B, Chaturvedi V, Li L et al.: Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18, 1185-1196 (1999).
109. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG: Allelotype of human bladder cancer. Cancer Res. 54, 531-538 (1994).
110. von Knobloch F, Hegele A, Brandt H, Olbert P, Heidenreich A, Hofmann R: Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int. J. Cancar 94, 67-72 (2001).
111. Seripa D, Parrella P, Gallucci M et al.: Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int. J. Cancer 95, 364-369 (2001).
112. Cajulis RS, Haines GK 3rd, Frias-hidvegi D, McVary K, Bacus JW: Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn. Cytopathol. 13, 214-223 (1995).
113. van der Poel HG, van Balken MR, Schamhart DH et al.: Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 51, 44-50 (1998).
114. Depraetere V, Goistein P: Fas and other cell death signaling pathways. Semin. Immunol. 9, 93-107 (1997).
115. Perabo FG, Mattes RH, Wirget A et al.: Soluble Fas and Fas-ligand in bladder cancer in vitro and in vibo. Urol. Oncol. 6, 163-169 (2001).
116. Mizutani Y, Yoshida O, Bonavida B: Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J. Urol. 160, 571-576 (1998).
117. Maas S, Warskulat U, Steinhoff C et al.: Decreased Fas expression in adyanced-stage bladder cancer is not related to p53 status. Urology 63, 392-397 (2004).
118. Lee SH, Lee JY, Park WS, Kim SY, Jang JJ, Yoo NJ: Transitional cell carcinoma expresses high levels of Fas ligand in vivo. BJU Int. 83, 698-702 (1999).
119. Svatek RS, Hemian MP, Lotan Y et al.: Soluble Fas - a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 106, 1701-1707 (2006).
120. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22, 8581-8589 (2003).
121. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC: Urine detection of survivin and diagnosis of bladder cancer. JAMA 285, 324-328 (2001).
122. Shariat SF, Casella R, Khoddami SM et al.: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J. Urol. 171, 626-630 (2004).
123. Schultz IJ, Kiemeney LA, Karthaus HF et al.: Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin. Chem. 50, 1425-1428 (2004).
124. Greider CW: Telomere length regulation. Annu. Rev. Biochem. 65, 337-365 (1996).
125. Blackburn EH: Telomeres and their synthesis. Science 249, 489-490 (1990).
126. Blackburn EH: Structure and function of telomeres. Nature 350, 569-573 (1991).
127. Morin GB: The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59, 521-529 (1989).
128. Ito H, Kyo S, Kanaya T, Takakura M, Inoue M, Namiki M: Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin. Cancer Res. 4, 1603-1608 (1998).
129. Kim NW, Piatyszek MA, Prowse KR et al.: Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015 (1994).
130. Ulaner GA, Hu JF. Vu TH, Giudice LC, Hoffman AR: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58, 4168-4172 (1998).
131. De Kok JB, Schalken JA, Aalders TW, Ruers TJ, Willems HL, Swinkels DW: Quantitative measurement of telomerase reverse transcriptase (hKERT) mRNA in urothelial cell carcinomas. Int. J. Cancer 87, 217-220 (2000).
132. Melissourgos N, Kastrinakis NG, Davilas I, Foukas P, Farmakis A, Lykourinas M: Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology 62, 362-367 (2003).
133. Wu X, Kakehi Y, Takahashi T, Habuchi T, Ogawa O: Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence. Int. J. Urol. 7, 210-217 (2000).
134. Cheng CW, Chueh SC, Chern HD: Diagnosis of bladder cancer using telomerase activity in voided urine. J. Formos. Med. Assoc. 99, 920-925 (2000).
135. Cassel A, Rahat MA, Lahat N, Lindenfield N, Mecz Y, Stein A: Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: an unfulfilled promise. J. Urol. 166, 841-844 (2001).
136. Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC: Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 82, 708-714 (1998).
137. Lee DH, Yang SC, Hong SJ, Chung BH, Kim IY: Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin. Cancer Res. 4, 535-538 (1998).
138. Dalbagni G, Han W, Zhang ZF et al.: Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Clin. Cancer Res. 3, 1593-1598 (1997).
139. Yokota K, Kanda K, Inoue Y, Kanayama H, Kagawa S: Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. Br. J. Urol. 82, 727-732 (1998).
140. Mayfield MP, Shah T, Flannigan GM, Hamilton Stewart PA, Bibby MC: Telomerase activity in malignant and benign bladder conditions. Int. J. Mol. Med. 1, 835-840 (1998).
141. Muller M, Krause H, Heicappell R, Tischendorf J, Shay JW, Miller K: Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin. Cancer Res. 4, 1949-1954 (1998).
142. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA: Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 47, 863-869 (1996).
143. Crawford ED, Leewansangtong S, Goktas S, Holthaus K, Baier M: Efficiency of prostate-specific antigen and digital rectal examination in screening using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate 38, 296-302 (1999).
144. Gustafsson O, Mansour E, Norming U, Carlsson A, Tornblom M, Nyman CR: Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer - a study of a randomly selected population of 2,400 men. Scand. J. Urol. Nephrol. 32, 373-377 (1998).
145. Filella X, Molina R, Ballesta AM, Gil MJ, Allepuz C, Rioja LA: Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study. Eur. J. Cancer 32A, 1125-1128 (1996).
146. Ito K, Kubota Y, Suzuki K et al.: Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations. Urology 55, 705-709 (2000).
147. Kihara T, Ito F, Kobayashi C et al.: Utility of prostate specific antigen (PSA) density in detecting prostate cancer in men showing gray zone serum PSA levels. Hinyokika Kiyo 43, 13-18 (1997).
148. Soloway MS: Editorial: bladder tumor markers, intravesical therapy and systemic chemotherapy. J. Urol. 166, 488-489 (2001).
149. Vriesema J, Poucki M, Kiemeney L, Witjes J: Patient's opinon about urine bound diagnositic tests versus urethrocytoscopy in the management of bladder cancer. A utility analysis. Urology 56, 793-797 (2000).
150. Sarosdy MF, Hudson MA, Ellis WJ et al.: Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 50, 349-353 (1997).
151. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Alterieri DC: Urine detection of survivin and diagnosis of bladder cancer. JAMA 285, 324-328 (2001).
152. Yoshida K, Sugino T, Tahara H et al.: Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 79, 362-369 (1997).
153. Sumi S, Arai K, Kitahara S, Yoshida KI: Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin. Chim. Acta 296, 111-120 (2000).
154. Sarosdy MF, Schellhammer P, Bokinsky G et al.: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J. Urol. 168, 1950-1954 (2002).
155. Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED: The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol. Oncol. 22, 16-19 (2004).
156. Halling KC, King W, Sokolova IA et al.: A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J. Urol. 164, 1768-1775 (2000).